Bryan E. Stuart
President and CEO
Bryan has 20 years of experience building innovative life sciences companies. He was most recently the Chief Business Officer of Civitas Therapeutics. At Civitas, Bryan was responsible for raising capital, business development, commercial and strategy functions, including the IPO and company sale of Civitas to Acorda Therapeutics (NASDAQ: ACOR). Civitas' lead program, CVT-301, was in Phase 3 clinical trials to treat devastating OFF-episodes associated with Parkinson’s disease. Civitas had raised over $100 million in equity capital from leading venture capital and crossover investors including Wellington, RA Capital, Adage, Orbimed, Sofinnova and Partner Funds amongst others.
Prior to joining Civitas, Bryan served as Chief of Corporate Development at EKR Therapeutics, a biopharmaceutical business focused on developing and commercializing therapies targeted towards the acute care market, which was sold to Cornerstone Therapeutics (NASDAQ: CRTX) in 2012.
Before EKR, Bryan was the Vice President of Corporate and Business Development and M&A for Ovation Pharmaceuticals. Ovation was a biopharmaceutical company focused on the development and commercialization of therapies targeted towards severe and rare diseases. The company was built through more than a dozen transactions and strategic partnerships and successfully developed multiple innovative products including Xenazine® for Huntington’s Disease, ONFI® for Lennox-Gaustat Syndrome and Sabril® for infantile spams. Ovation and was sold to H. Lundbeck A/S in 2009.
Bryan began his career as a healthcare investment banker for William Blair & Company. He holds a Bachelor of Science in Finance with high honors from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Kellogg School of Management at Northwestern University
Vice President, Technical Operations
Chris brings over 25 years of industry experience in the development biopharmaceutical products, working with industry leading and emerging life sciences companies. Chris joins Kastle from Baxalta where he coordinated all Life-Cycle Management activities associated with their flagship immunology product. Prior to Baxalta, Chris provided consulting services and was the acting Chief Scientific Officer for several newly formed companies, including Sagitta Biotherapeutics and VivacelleBio, Inc.
Chris was previously the Executive Vice President and Chief Scientific Office for Fresenius Kabi, USA, where he had responsibility for the development of a broad portfolio of small molecule injectable generics. In this role, Chris led efforts resulting in the approval of numerous ANDA’s as well as several complex 505(b)2 products. Earlier in his career he worked at both Eli Lilly and Armour Pharmaceutical Company, where he began as a bench scientist and went on to gain deep understanding of all facets of drug product development including CMC and clinical development, project management, quality assurance, regulatory affairs and technical operations as he held increasing levels of R&D management responsibility.
Chris holds an undergraduate degree in chemistry from the University of Northern Iowa and earned a Master of Science and Doctorate degree in chemistry from the University of California, San Diego.
Vice President of Finance and Controller
Scott comes with over 25 years of experience in a variety of companies and industries, including 18 years of progressive Finance and Commercial Strategy roles in life sciences companies. Most recently Scott was the Vice President of Strategic Finance and Planning for Takeda Pharmaceuticals International GmbH based in Zurich, Switzerland. Scott was responsible for leading Global Financial Planning & Analysis for Takeda’s commercial organization outside of Japan and the related successful integration of Nycomed’s commercial and manufacturing entities following the 2011 acquisition. Scott also led several post-integration Global-level initiatives focused on operations investment strategy and margin optimization; as well as development and harmonization of the company-wide financial information infrastructure, consolidation and systems environment.
Prior to Takeda, Scott created and led the Finance and HR organizations for an angel investor backed software startup company focused on e-learning in the industrial workplace. Scott’s experience also includes PricewaterhouseCoopers where he consulted to a variety of businesses on Financial Planning and Operational Efficiency initiatives. Scott began his career in a Financial Development Program at Baxter Healthcare.
Scott holds bachelor’s degrees in Accountancy and Economics from the University of Illinois at Urbana-Champaign and is a CPA. Scott earned his Master of Business Administration degree from the University of Chicago Booth Graduate School of Business.
Head of Business Development
Chris’ career has focused on advising and investing in late-stage life sciences companies. Most recently, he was a member of the OrbiMed Advisors structured investments team which managed ~$2.0 billion. The team at OrbiMed worked closely with public and private companies to finance the development, launch, or acquisition of innovative products. Chris’ experience includes investments in multiple therapeutic areas, medical devices, and diagnostics.
Prior to joining OrbiMed, he was at Cowen Healthcare Royalty Partners. At Cowen, he invested in a range of transactions including royalty monetizations, growth equity investments, and off-balance sheet financings for larger pharmaceutical companies. Prior to Cowen, he was an analyst in the investment banking groups of Leerink Partners and Bear Stearns. Chris’ investment banking experiences includes M&A advisory, and raising money for clients in the debt and equity capital markets.
Chris holds a B.A. from Hamilton College in economics and communication.